1. Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells. (6th March 2017) Authors: Fuh, Franklin K; Looney, Caroline; Li, Dongwei; Poon, Kirsten A; Dere, Randall C; Danilenko, Dimitry M; McBride, Jacqueline; Reed, Chae; Chung, Shan; Zheng, Bing; Mathews, William Rodney; Polson, Andrew; Prabhu, Saileta; Williams, Marna Journal: British journal of pharmacology Issue: Volume 174:Number 8(2017) Page Start: 628 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Bioanalytical assay strategies for the development of antibody–drug conjugate biotherapeutics. (January 2013) Authors: Kaur, Surinder; Xu, Keyang; Saad, Ola M; Dere, Randall C; Carrasco-Triguero, Montserrat Journal: Bioanalysis Issue: Volume 5:Number 2(2013) Page Start: 201 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Issue 6 (June 2015) Authors: Palanca-Wessels, Maria Corinna A; Czuczman, Myron; Salles, Gilles; Assouline, Sarit; Sehn, Laurie H; Flinn, Ian; Patel, Manish R; Sangha, Randeep; Hagenbeek, Anton; Advani, Ranjana; Tilly, Herve; Casasnovas, Olivier; Press, Oliver W; Yalamanchili, Sreeni; Kahn, Robert; Dere, Randall C; Lu, Dan; J... Journal: Lancet oncology Issue: Volume 16:Issue 6(2015:Jun.) Page Start: 704 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗